KYMR - Kymera Therapeutics Inc
Kymera Therapeutics Inc Logo

KYMR - Kymera Therapeutics Inc

https://www.kymeratx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.

52W High
$53.27
52W Low
$19.45
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
2.18
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-9.49
EV/Revenue (<3 favorable)
56.61
P/S (TTM) (<3 favorable)
69.58
P/B (<3 favorable)
3.20
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
2.45%
Institutions (25–75% balanced)
109.99%
Shares Outstanding
71,498,000
Float
46,960,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
44,711,000
Gross Profit (TTM)
-246,159,008
EPS (TTM)
-3.49
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-7.37%
ROE (TTM) (>15% strong)
-0.33%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.55
Momentum
Bearish momentum
Value
-0.1141
Previous
-0.2769
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025